2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Neprilysin
  5. Neprilysin Inhibitor

Neprilysin Inhibitor

Neprilysin Inhibitors (38):

Cat. No. Product Name Effect Purity
  • HY-18204A
    Sacubitril/Valsartan
    		Inhibitor 99.99%
    Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis.
  • HY-15407
    Sacubitril
    		Inhibitor 99.65%
    Sacubitril (AHU-377) is a potent and orally active NEP (neprilysin) inhibitor with an IC50 of 5 nM. Sacubitril is a component of the heart failure medicine LCZ696. Sacubitril can be used for the research of heart failure, hypertension and COVID-19.
  • HY-17620
    Sacubitrilat
    		Inhibitor 99.00%
    Sacubitrilat (Desethyl Sacubitril) is an active neprilysin (NEP) inhibitor.
  • HY-17399
    Racecadotril
    		Inhibitor 99.83%
    Racecadotril (Acetorphan) is a neutral endopeptidase (NEP) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with Kis of 4500 and 6.1 nM, , respectively. Antidiarrheal agent.
  • HY-N2021A
    Phosphoramidon Disodium
    		Inhibitor 99.83%
    Phosphoramidon Disodium, a microbial metabolite, is a specific metalloprotease thermolysin inhibitor with an IC50 of 0.4 μg/mL. Phosphoramidon Disodium also inhibits endothelin-converting enzyme (ECE), neutral endopeptidase (NEP), and angiotensin-converting enzyme (ACE) with IC50 values of 3.5, 0.034, and 78 μM, respectively.
  • HY-164704
    JA2
    		Inhibitor
    JA2 is an inhibitor of Metalloendopeptidase 24.15 that can potentiate the hypotensive response to bradykinin in rat.
  • HY-117961
    Candoxatrilat
    		Inhibitor
    Candoxatrilat (UK 73967) is an orally active inhibitor of neutral endopeptidase. By elevating the levels of atrial natriuretic peptides, Candoxatrilat exerts its diuretic and natriuretic effects. Candoxatrilat is utilized in the research of heart failure.
  • HY-W013375
    Thiorphan
    		Inhibitor 99.67%
    Thiorphan is a selective NEP (neprilysin) inhibitor with an IC50 of 6.9 nM.
  • HY-15407A
    Sacubitril hemicalcium salt
    		Inhibitor 99.69%
    Sacubitril hemicalcium salt (AHU-377 hemicalcium salt) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril hemicalcium salt is a component of the heart failure medicine LCZ696.
  • HY-W345510
    Opiorphin
    		Inhibitor 98.83%
    Opiorphin, an opioid peptide, is a potent enkephalin-inactivating zinc ectopeptidases in human inhibitor. Opiorphin inhibits two enkephalin-catabolizing ectoenzymes, human neutral ecto-endopeptidase, hNEP (EC 3.4.24.11) with an IC50 value of 11 μM, and human ecto-aminopeptidase, hAP-N (EC 3.4.11.2). Opiorphin displays potent analgesic activity by activating endogenous opioid-dependent transmission.
  • HY-15407B
    Sacubitril sodium
    		Inhibitor 99.95%
    Sacubitril sodium is a potent and orally active NEP (neprilysin) inhibitor, with an IC50 of 5 nM. Sacubitril sodium enhances the tone of the natriuretic peptide (NP) system and exerts significant antihypertensive effects. Sacubitril sodium is a component of the heart failure medicine LCZ696. Sacubitril sodium can be used for the research of heart failure, hypertension and COVID-19.
  • HY-123348
    Sampatrilat
    		Inhibitor 99.22%
    Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP). Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM). Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation.
  • HY-19649
    Candoxatril
    		Inhibitor 99.56%
    Candoxatril is a neutral endopeptidase (NEP) inhibitor.
  • HY-114412A
    TD-0212 TFA
    		Inhibitor 98.44%
    TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP.
  • HY-114412
    TD-0212
    		Inhibitor
    TD-0212 (compound 35) is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP.
  • HY-15407AS1
    Sacubitril-d4 hemicalcium salt
    		Inhibitor 98.78%
    Sacubitril-d4 hemicalcium salt is the deuterium labeled Sacubitril hemicalcium salt (HY-15407A). Sacubitril hemicalcium salt is a potent NEP inhibitor with an IC50 of 5 nM.
  • HY-17399S
    Racecadotril-d5
    		Inhibitor
    Racecadotril-d5 is the deuterium labeled Racecadotril. Racecadotril (Acetorphan) is a neutral endopeptidase (NEP) inhibitor. Racecadotril and its active metabolite Thiorphan inhibits purified NEP activity from mouse brain with Kis of 4500 and 6.1 nM, , respectively. Antidiarrheal agent[1].
  • HY-N2021
    Phosphoramidon
    		Inhibitor
    Phosphoramidon, a microbial metabolite, is a specific metalloprotease thermolysin inhibitor with an IC50 of 0.4 μg/mL. Phosphoramidon also inhibits endothelin-converting enzyme (ECE), neutral endopeptidase (NEP), and angiotensin-converting enzyme (ACE) with IC50 values of 3.5, 0.034, and 78 μM, respectively.
  • HY-15407S3
    Sacubitril-13C4
    		Inhibitor
    Sacubitril-13C4 (AHU-377-13C4) is a 13C-labeled version of Sacubitril (HY-15407). Sacubitril is an orally active inhibitor of neprilysin NEP (IC50=5 nM). Sacubitril is used in research on heart failure, hypertension and COVID-19.
  • HY-15407S
    Sacubitril-d4
    		Inhibitor
    Sacubitril-d4 is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.